Physician profile
Michael D Settecase
NPI 1447368055
$5,243.65
in general payments reported to CMS, 2019-2025
34 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $408 · 2021: $393 · 2022: $653 · 2023: $607 · 2024: $1,052 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,474.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $687.31 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $365.96 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $326.16 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $304.71 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $254.15 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $235.70 | 2019-2024 | |
| Exact Sciences Corporation | $223.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $152.72 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $143.89 | 2019-2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.14 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $134.49 | 2019-2022 | |
| Abbvie INC. | $87.38 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.06 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $68.26 | 2024-2025 | Camzyos, Eliquis |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $67.61 | 2024 | Voquezna |
| Zyla Life Sciences, INC. | $56.70 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $42.24 | 2019-2025 | Zoryve |
| Sunovion Pharmaceuticals INC. | $41.11 | 2019 | |
| Sanofi Pasteur INC. | $37.19 | 2020-2021 | |
| Amarin Pharma, INC. | $36.34 | 2020-2022 | |
| Lundbeck LLC | $30.05 | 2024 | Rexulti |
| Corcept Therapeutics | $28.28 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.40 | 2021 | |
| Dexcom, INC. | $25.82 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $25.33 | 2023 | Gemtesa |
| Dynavax Technologies Corporation | $24.08 | 2022 | |
| Sun Pharmaceutical Industries INC. | $23.30 | 2019 | |
| Kyowa Kirin, INC. | $21.13 | 2024 | Crysvita |
| Allergan, INC. | $18.71 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.84 | 2020 | |
| Biogen, INC. | $15.23 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.16 | 2024 | |
| Melinta Therapeutics, LLC | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Settecase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.